Gene: DIPK1A
Official Full Name: divergent protein kinase domain 1Aprovided by HGNC
Gene Summary: This gene encodes a member of the FAM69 family of cysteine-rich type II transmembrane proteins. These proteins localize to the endoplasmic reticulum but their specific functions are unknown. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Nov 2011]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO18279 | DIPK1A Knockout cell line (HeLa) | Human | DIPK1A | 1:3~1:6 | Negative | Online Inquiry |
KO18280 | DIPK1A Knockout cell line (HCT 116) | Human | DIPK1A | 1:2~1:4 | Negative | Online Inquiry |
KO18281 | DIPK1A Knockout cell line (HEK293) | Human | DIPK1A | 1:3~1:6 | Negative | Online Inquiry |
KO18282 | DIPK1A Knockout cell line (A549) | Human | DIPK1A | 1:3~1:4 | Negative | Online Inquiry |
DIPK1A Gene Knockout Cell Lines represent a cutting-edge tool in molecular biology, specifically designed to facilitate the study of the DIPK1A gene's functions and its implicative roles in various cellular processes. These cell lines have been meticulously engineered using CRISPR-Cas9 technology to achieve precise gene knockout, enabling researchers to observe the phenotypic consequences of DIPK1A loss-of-function in a controlled environment.
The primary function of these cell lines is to serve as a robust model for investigating the biological mechanisms whereby the DIPK1A gene influences cellular activities, including but not limited to signal transduction, cell proliferation, and metabolic regulation. By eliminating the expression of DIPK1A, researchers can elucidate its involvement in pathophysiological conditions, including cancer and metabolic disorders, thereby providing insight into potential therapeutic targets.
In the context of both research and clinical applications, these knockout cell lines hold significant scientific importance. They facilitate high-throughput screening of pharmaceuticals that may target pathways linked to DIPK1A, contributing to drug discovery efforts. Additionally, they are invaluable in the realm of gene therapy studies, allowing for the validation of gene-editing approaches and the assessment of potential off-target effects.
What sets our DIPK1A Gene Knockout Cell Lines apart from alternative models is their high specificity and reliability, coupled with our commitment to rigorously tested products. These cell lines are derived from well-characterized human cell lines, ensuring that results are both reproducible and relevant to human biology. Furthermore, our knockout cell lines come with comprehensive documentation, including detailed protocols and user guides, which enhances their usability in diverse experimental designs.
For researchers and clinicians focused on unraveling the complexities of gene function and disease mechanisms, our DIPK1A Gene Knockout Cell Lines provide an indispensable resource. Leveraging our extensive experience in the field of gene editing and molecular biology, we ensure that our products meet the highest standards of quality and performance, enabling groundbreaking discoveries and advancements in health care.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.